Stephen Auerbach
NewYork–Presbyterian Hospital
14 Papers
78 Citations
Stephen Auerbach is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Mirabegron & Placebo. The author has an hindex of 8, co-authored 14 publications.
Chat about Author
Papers
Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
TL;DR: Once daily mirabegron in a 50 or 100 mg dose is an effective treatment for overactive bladder symptoms with a low occurrence of side effects.
438
Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
Kevin T. McVary,Claus G. Roehrborn,Jed Kaminetsky,Stephen Auerbach,Barton Wachs,Jay M. Young,Anne Esler,Gregory D. Sides,Bela S. Denes +8 more
TL;DR: Tadalafil significantly improved the mean change from baseline in International Prostate Symptom Score at 6 weeks and at 12 weeks and made significant improvements in the Benign Prostatic Hyperplasia Impact Index (significant at12 weeks) vs placebo.
376
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Russell Blair Egerdie,Stephen Auerbach,Claus G. Roehrborn,Pierre Costa,Martin Sanchez Garza,Anne Esler,David G. Wong,Roberta J. Secrest +7 more
TL;DR: Tadalafil 5 mg significantly improved both ED and BPH-related outcomes through 12 weeks and was well tolerated, according to results of this multinational Phase 3 study.
147
Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial
Victor W. Nitti,Christopher R. Chapple,C. Walters,Mary Beth Blauwet,Sender Herschorn,Ian Milsom,Stephen Auerbach,Piotr Radziszewski +7 more
TL;DR: To evaluate the safety and tolerability of the β3‐adrenoceptor agonist, mirabegron, in patients with overactive bladder (OAB).
75